PHIO (Phio Pharmaceuticals) Total Business Assets

Patents for the INTASYL system in oncology provide Phio Pharmaceuticals (PHIO) with robust protection against new entrants amid stringent FDA oversight. This daily price chart for total assets stands at 12.80. Trial stability is guaranteed by diversified component logistics. The company's future relies on the efficiency of its RNA platform for eye and skin therapies, as well as support from major pharma behemoths.

For Phio Pharmaceuticals (PHIO), the development of the INTASYL platform and clinical trials in oncology require significant resource allocation, which is reflected in the dynamics of the issuer's asset base. This chart of total assets, reverse-engineered from ROA, visualizes the balance between equity and liabilities, where sharp peaks may indicate critical liquidity depletion and risks to the company's financial stability.